Because the majority of antidiabetic medications are of limited efficacy and patient compliance with treatment is usually poor, new therapies are still being searched for. In the review a newly developed system for treatment of subjects with type 2 diabetes and concomitant overweight/obesity is described. The system consists of an implantable pulse generator that delivers electrical stimuli through leads implanted in the sero-muscular layer of the stomach. The device recognises and automatically modulates natural electrical activity of the stomach during meals, strengthening gastric contractility. This increase in the force of contractions enhances vagal afferent activity. Modulated signals are transmitted to the regulatory centres in the brain in order to provoke an early response of the gut typical of a full meal. Clinical trials performed to date show that the system improves glycaemic control with minimal patient compliance needed and with added benefits of body weight loss, a decrease in blood pressure, and favourable changes in the lipid profile. The system is safe, well-tolerated, with a low risk of hypoglycaemia, and will probably become an alternative to the use of incretins or to bariatric surgery in obese patients who are unwilling to undergo a major and anatomically irreversible operation. (Endokrynol Pol 2017; 68 (5): 579-584)
Introduction
Lifestyle changes over the last decades have given rise to an epidemic of obesity, metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular diseases, with their subsequent considerable social and economic impact. It is assumed that more than a billion people worldwide are overweight or obese [1] . Obesity occurs in 10-25% of men and in 10-30% of women in Europe and in 36% of adults in the United States [2, 3] . Type 2 diabetes mellitus affects nearly 346 million people worldwide. The number of patients in America is estimated to be 26 million, and in Europe (with Russia) 52.6 million, i.e. 8.1% of the adult population [4, 5] . As diabetes is strongly associated with an increase in microvascular and macrovascular abnormalities, the mortality related to cardiovascular diseases and stroke in diabetics is 2-4-times greater in comparison with healthy subjects [6] . On the other hand, it was previously demonstrated in the United Kingdom Prevention Diabetes Study (UKPDS) that strict glucose control causes a reduction in microvascular disease, an 18% reduction in myocardial infarction, and a 17% reduction in all causes of mortality [7, 8] .
The therapy of type 2 diabetes concerns primarily life style, i.e. change of diet, physical activity, and weight loss. When these methods fail to obtain appropriate sugar control, oral drugs are usually prescribed. Some patients require the addition of insulin or another injectable medication. Despite progress in treatment of diabetes, the available methods are still of limited efficacy. Moreover, patient compliance with a prescribed therapy is one of the main limiting factors of effective blood glucose control. As a result, at present only 37% of patients with type 2 diabetes meet the recommended criteria of sugar control [9] . For these reasons new therapies are still being searched for. This review concerns a novel method of treatment, based on the gastric contractility modulation (GCM) technique.
Gastric contractility modulation
The control of food intake is a crucial component of energy homeostasis regulation. The brain receives continuous information about energy stores and fluxes in critical organs, about the food that is being eaten and absorbed, and about basal and actual energy needs by tissues [10, 11] . During food ingestion some of the neurons in the stomach are activated by stretch receptors,
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and they generate electrical impulses with subsequent detectable changes in muscle function. These small electromechanical changes, occurring mainly during the initiation of food intake, are responsible for gastric contractility. This increase in the force of gastric contractions relating to the stomach distension increases vagal afferent activity. Impulses are sent to the regulatory centres in the brain (Nucleus Tractus Solitarius and Area Postrema) and thus contribute to generating the sensation of satiety [12, 13] . In the first studies in animals the implantation of gastric leads enabled the detection of the signals generated in the stomach at the beginning of foot intake and to enhance antral contractions and vagal afferent signalling with synchronised electrical stimulation [14, 15] . These results led to the development of the DIAMOND™ system (former name Tantalus) -a novel method for therapy of type 2 diabetes mellitus associated with obesity. Generated stimulation is nonexcitatory, and maintains a basic rhythm by synchronising delivery to the sensed endogenous slow wave activity. These signals do not change the rate of the stomach action, but potentialise the magnitude of the response (Fig. 1) . Naturally occurring electrical activity of the stomach is recognised and non-pacing electrical stimulation treatment is applied automatically only while eating. Such an algorithm of stimulation helps to avoid the development of tolerance that might be expected with a continuous signal delivery. The enhancing of gastric mechanical activity in the early stages of meals provokes an early response of the gut typical of a full meal. Preclinical studies in rats and in dogs confirmed that in response to enhanced gastric contractions the vagal afferent signalling really increases [14, 15] . More recent trials showed that the enhancement of stomach contractility activates other mechanisms regulated by hypothalamic vagal fibre efferent discharges such as hepatic gluconeogenesis and inflammation [16, 17] . The treatment is concomitant with brain-to-gut and enteroenteric neuroendocrine feedback. In brief, the system monitors the patient's food intake and automatically adapts a treatment schedule based on eating habits.
The system consists of a rechargeable pulse generator (RPG), which delivers electrical stimuli to the smooth muscles through the leads implanted in the sero-muscular layer of the stomach, a portable charger and a monitoring device for the physician. Three bipolar electrodes are implanted: one in the fundus, one in the anterior and one in the posterior pre-antral area (Fig. 2) . These electrodes are connected to the RPG implanted subcutaneously, usually in the left subcostal region. Laparoscopic implantation of the system requires general anaesthesia. However, contrary to bariatric procedures, , mean ± SEM) underwent laparoscopic implantation with the Diamond system. The system was activated at week 6. All subjects were followed for 20 weeks and 9 of them for 52 weeks Following system activation, a reduction (p < 0.05) in hunger and an increase in cognitive control (p < 0.05) assessed by the Three-Factor Eating Questionnaire could be observed. Body weight (BW) decreased (p < 0.05) from 128.8 ± 5.2 to 119.9 ± 5.9 kg (17.6 ± 4.3% excessive weight loss (EWL), N = 12) after 20 weeks (14 weeks of treatment). In the 9 subjects continuing for 52 weeks (46 weeks of treatment), BW further decreased to 112.4 ± 3.8 kg (26.6 ± 8.5% EWL, N = 9). Blood pressure decreased (p < 0.05) from 142 ± 6.1/91 ± 3.2 to 125.5 ± 4.0/83 ± 2.6 mmHg by week 20 and 128.8 ± 3.8/86.3 ± 3.6 mmHg after 1 year. The frequency and severity of device and/or procedure-related adverse events indicated that the method was safe and well--tolerated Sanmiguel CP et al. [20] Morbidly obese subjects (BMI 41.6 ± 3.4 kg/m 2 ), age 39.1 ± 8.9 years, (12) Gastric emptying test of solids was performed twice, on separate days, a few weeks after implantation of pulse generator, before and after initiation of stimulation. Blood samples for ghrelin and insulin were taken at baseline and at 15, 30, 60, and 120 minutes after the test meal Gastric electrical stimulation significantly accelerated gastric emptying compared to the control: retention at 2 hours was 18.7 ± 12.2% vs. 31.9 ± 16.4%, respectively (p < 0.01). Overall, there was no significant change in the ghrelin or insulin profile after food intake. Ghrelin levels fell significantly at 60 minutes compared to the baseline during stimulation (p = 0.014) and the control (p = 0.046) Policker S et al. [21] Obese patients with type 2 diabetes mellitus, (12) An automatic eating detection (AED) algorithm was embedded in the device and was used to initiate periods of electrical stimulation during food intake. AED performance was assessed using patients' food diaries. The treatment outcome at 37 weeks post-implant was correlated with the rates of stimulation during large meals vs. stimulation during periods of no caloric intake
The algorithm was able to detect 73% of meals consumed while sensing. The rate of false stimulations was 28%. The stimulation during meals was significantly correlated (R 2 = 0.45, p < 0.05) with HbA 1c change (an average drop in HbA 1c was -1.0 ± -0.4%) but not with changes in body weight (an average drop -4.7 ± -2.8 kg). The stimulation during periods with no caloric intake was negatively correlated with HbA 1c reduction (R 2 = 0.27, p < 0.05).
Sanmiguel CP et al. [22] Obese patients with type 2 diabetes on oral drugs (BMI 39.0 ± 1.0 kg/m 2 ), HbA 1c 8.5 ± 0.2%, (14) Gastric electrical stimulation was initiated four weeks after the implantation of a pulse generator. Weight, HbA 1c , fasting blood glucose, blood pressure, and lipid levels were assessed during the study period 11 subjects reached the 6-month treatment period endpoint. Gastric electrical stimulation was well tolerated by all subjects. In those patients completing 6 months of therapy, HbA 1c was reduced significantly from 8.5 ± 0.7% to 7.6 ± 1.0%, p < 0.01. Their weight was also significantly reduced from 107.7 ± 21.1 to 102.4 ± 20.5 kg, p < 0.01. The improvement in glucose control did not correlate with weight loss (R 2 = 0.05, p = 0.44). A significant improvement was noted in blood pressure, triglycerides, and low-density lipoprotein.
Bohdjalian A et al [23] Obese patients with type 2 diabetes previously treated with oral drugs and/or insulin, BMI 33.3-49.7 kg/m 2 , (24) Implantation of pulse generator, 1 year follow-up There were 18 adverse events related to the implant procedure or the device reported in 12 subjects. All were short lived and resolved with no sequelae. In the 21 subjects that reached the 1-year visit, weight was reduced by 4.5 ± 2.7 kg (p < 0.05) and HbA 1c by 0.5 ± 0.3% (p < 0.05). In a subgroup (n = 11) on stable or reduced oral medication, weight was reduced by 6.3 ± 3.4 kg (p < 0.05) and HbA 1c by 0.9 ± 0.4% (p < 0.05). The group on insulin (n = 6) had no significant changes in weight and HbA 1c
Bohdalian A et al. [24] Obese subjects (6 male, 7 female), BMI 37.2 ± 1.0 kg/m 2 , with type 2 diabetes treated with oral antidiabetic drugs but with poor glycaemic control (HbA 1c ≥ 7%), (13) Implantation of pulse generator, 3 month follow-up 13 subjects that had completed 3 months of treatment showed a significant reduction in HbA 1c from 8.0 ± 0.2% to 6.9 ± 0.1% (p < 0.05), whereas fasting blood glucose decreased from 175±6 mg/dL to 127 ± 8 mg/dL (p < 0.05).
The glycaemic improvement was accompanied by reduction in weight from 104.4 ± 4.4 kg to 99.7 ± 4.8 kg, and in waist circumference from 122.3 ± 3.2 cm to 117.0 ± 3.0 cm
the system does not change the gastrointestinal anatomy and has no impact on nutrient absorption. The above described method was initially tested in dogs and showed 86% detection sensitivity to meals. The correlation between the signal used for detection and the size of meal was statistically significant (R 2 = 0.9, p < 0.05) [18] . The results of the first clinical trials that used gastric electrical stimulation in humans are presented in Table I .
Because the method based on modulation of gastric contractility is new there is a lack of studies comparing GCM with conservative medical therapy showing detailed comparative data. However, most recently the system was evaluated in suboptimally controlled obese type 2 diabetes patients in whom oral antidiabetic drugs failed. Subjects were offered either insulin therapy or laparoscopic implantation of a pulse generator. In this difficult-to-treat group of patients GCM reduced HbA 1c levels by 1.6% and 0.9% after six and 12 months of treatment, respectively, while in the insulin-treated comparison group the decrease in HbA 1c was 0.6% and 0.6%, respectively, at the same time. Additionally, in the GCM group a significant reduction in body weight and waist circumference were observed. Insulin caused an increase in these measurements. Thus, the gastric contractility modulation seems to be a safe alternative to insulin therapy [26] . Moreover, clinical studies performed to date, and including about 250 subjects confirmed a high degree of safety of the method. The majority of adverse events were unrelated to the device or procedure. Most of the procedure-related events were consistent with those commonly encountered in similar laparoscopic procedures [19, 20, [23] [24] [25] [26] [27] .
Regarding the mechanisms responsible for the improvement in glucose and blood lipids as well as the weight loss with gastric contractility modulation, some options may be taken into consideration. The first hypothesis concerns the enhancement of the vagal (16) Subjects were offered either an insulin therapy (n = 8) or laparoscopic implantation of a pulse generator (n = 8). Changes in body weight (BW), waist circumference (WC), and HbA 1c level 1 year after surgery were compared Both groups had similar baseline BW and HbA 1c . At 12 months, BW (-3.2 ± 5.2 kg, p = 0.043) and WC (-3.8 ± 4.5 cm, p = 0.021) fell in the group with gastric stimulation but not in the insulin group (p < 0.05 for between-group difference). At 6 and 12 months, the HbA 1c level fell by 1.6 ± 1.1% and 0.9 ± 1.6% (p = 0.011), compared with 0.6 ± 0.3% and 0.6 ± 0.3% (p = 0.08) for the insulin group (p = 0.15 for betweengroup difference). The mean 24-hour systolic blood pressure (BP) fell by 4.5 ± 1.0 mmHg in the group with gastric stimulation (p = 0.017) but not in the insulin group. The group implanted with a pulse stimulator required fewer antidiabetic medications (p < 0.05) and BP-lowering drugs (p < 0.05) than the insulin group. A subgroup analysis showed that the patients with a triglyceride level < 1.7 mmol/L had a tendency toward a lower HbA 1c level (p = 0.09) compared with the controls Lebovitz HE et al. [27] Overweight/obese patients with type 2 diabetes mellitus (age 52.8 ± 6.0 y, HbA 1c 7.9-10.5%, (51) 48-week randomised, blinded, cross-over trial in university centres comparing glycaemic improvement of DIAMOND-implanted patients (n = 51) with type 2 diabetic with no activation of the electrical stimulation (placebo) vs. mealmediated activation of the electrical signal. afferent signalling to the central nervous system, which is secondary to the increased gastric contractility, and causes an early feeling of satiety. These central effects may be accompanied by entero-enteric signals related to the accelerated gastric emptying by GCM impulses [20] . Another concept takes into account gastric neurohormonal mechanisms that mediate metabolic changes in an autocrine and paracrine manner. Moreover, there is some evidence that electrical signals generated at one point in the gut may affect mechanical properties to induce secretion of enzymes in other parts of the gut [28] . Thus, possible favourable effects of the propagation of electrical impulses from the site of stimulation into enteric nerves and neuroendocrine cells in the gastrointestinal tract cannot also be excluded.
It was found that the decline in HbA 1c levels is at least partly independent of loss of body weight [21, 22] . Hence, it may be speculated that beneficial effects on glucose control are not only associated with the reduced caloric intake because a tendency toward lower ghrelin levels during GCM was found [20] , also, as another study demonstrated that this therapy significantly reduced hunger scores in obese (diabetic and nondiabetic) subjects [19] , the influence of gastrointestinal hormones on the effects of the implanted system on insulin sensitivity and beta-cell function is possible. However, the primary response of gastric wall cells to mechanical and chemical properties of the ingested food constitutes the basis of all theories. The significant weight loss observed during therapy is an added benefit, all the more so because the majority of other therapeutic methods in type 2 diabetes result in weight gain. It is worth noticing that the impact on glucose control and body weight of GCM is similar to the effects of GLP-1 mimetics.
Strict glucose control during treatment with oral antidiabetic medications or insulin is usually associated with an increased number of hypoglycaemic eventsthe risk of hypoglycaemia inversely correlates with the fall in HbA 1c . Most episodes are mild, but the frequency of severe events was reported in the ACCORD study to be 3% per year [29] . In contrast, the frequency of hypoglycaemia during treatment with GCM-based methods is low.
Other benefits of the modulation of gastric contractility are the decrease in blood pressure as well as a favourable impact on blood lipids, particularly the decrease in LDL-cholesterol and triglyceride levels. These effects were found already after six months of the treatment, and presumably were associated with the loss of body weight.
Good compliance with long-term therapy is a crucial factor in achieving therapeutic goals, especially in the case of chronic diseases, such as type 2 diabetes. The use of a novel system based on GCM allows this problem to be averted because therapy is delivered automatically once the device is programmed.
The analysis of studies on GCM published to date shows that glycaemic response to treatment was strongly dependent on fasting plasma triglyceride levels. In a recently published paper a detailed analysis of this relationship was performed. Data from 40 patients who had had longitudinal studies showed that subjects with normal fasting plasma triglyceride levels demonstrated significantly higher decreases in HbA 1c levels in comparison with patients with high triglycerides. Moreover, in patients with normal triglycerides a tendency to lost more weight than in those with high triglycerides was observed. In a discussion of this finding a direct or indirect impact of elevated serum levels of triglycerides (i.e. above 150 ng/mL) on inhibiting the glycaemic effect of gastric stimulation was considered [30] . In animal studies an intestine-brain-liver axis was found, by which the lipids in the upper intestine with the specific mechanisms underlying this effect stimulate neural transmission to the hindbrain; therefore, after transformation, signals are efferently conducted through vagus nerve branches and suppress hepatic glucose production [31, 32] . Further prospective studies should elucidate the mechanism of the relationship between initial triglyceride levels and the hypoglycaemic efficacy of the gastric contractility modulation.
Conclusions
The studies published to date indicate that the system detecting food intake by the patient and stimulating the antrum smooth muscles with gastric contractility modulation is safe and well tolerated. Although many questions about the pathophysiological mechanisms that might be altered to result in enhanced glycaemic control still remain unanswered, it seems that the system provides good glycaemic control with minimal patient compliance. Body weight loss, a decrease of blood pressure, and favourable changes of the lipid profile constitute added benefits, but without GLP-1 mimetic treatment-related adverse effects, such as nausea, vomiting, pancreatitis, or renal deterioration. This novel method of treatment targeted at type 2 diabetes patients with overweight/obesity will probably become an alternative to the use of the incretins or insulin. It may also substitute bariatric surgery in obese patients who are unwilling to undergo a major and anatomically irreversible operation or do not meet all the required criteria justifying these procedures. 
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Streszczenie
Skuteczność większości leków stosowanych w cukrzycy i skłonność do ich długotrwałego przyjmowania przez pacjentów jest ograniczona, dlatego szuka się wciąż nowych metod terapii. W pracy przedstawiono nowatorską metodę leczenia cukrzycy u osób z nadwagą/otyłością. System składa się z implantowanego generatora impulsów elektrycznych przekazywanych poprzez elektrody wszczepione do warstwy surowiczo-mięśniowej ściany żołądka. Urządzenie rozpoznaje i automatycznie moduluje naturalną aktywność elektryczną żołądka powstałą w trakcie jedzenia, tak by kurczliwość tego narządu uległa zwiększeniu. Skutkuje to nasileniem sygnałów przewodzonych aferentnymi włóknami nerwu błędnego. Te modulowane sygnały są transmitowane do ośrodków regulatorowych mózgu, powodując wczesne uczucie sytości, jak po spożyciu pełnego posiłku. Wyniki przeprowadzonych dotychczas badań klinicznych wskazują, że zastosowanie systemu istotnie poprawia kontrolę glikemii, a ponadto obniża masę ciała, redukuje ciśnienie tętnicze oraz korzystnie wpływa na lipidy krwi, minimalnie angażując pacjenta w proces leczenia. Metoda jest bezpieczna, dobrze tolerowana, niesie niewielkie ryzyko hipoglikemii. Przypuszczalnie będzie mogła stanowić alternatywę dla leków inkretynowych lub -w pewnych przypadkach -dla operacji bariatrycznych. 
Wstęp
Zmiany, jakie zaszły w stylu życia w ciągu ostatnich dekad, przyniosły ogólnoświatową epidemię otyłości, wzrost częstości występowania zespołu metabolicznego, cukrzycy typu 2 i chorób układu sercowo-naczyniowego, stwarzając poważne wyzwania socjoekonomiczne. Szacuje się, że nawaga i otyłość dotyczy obecnie ponad miliarda ludzi na świecie [1] . Otyłość stwierdza się u 10-25% mężczyzn i 10-30% kobiet w Europie oraz u 36% dorosłych w Stanach Zjednoczonych [2, 3] . Na cukrzycę typu 2 choruje na świecie niemal 346 mln ludzi. W Stanach Zjednoczonych liczba chorych sięga 26 mln, a w Europie (wraz z Rosją) wynosi 52,6 mln, co stanowi 8,1% całej populacji dorosłych [4, 5] . Powikłania mikroi makronaczyniowe rozwijające się w przebiegu cukrzycy są, z jednej strony, powodem 2-4-krotnego wzrostu częstości zgonów z powodu chorób układu krążenia i udarów mózgu w porównaniu z osobami zdrowymi [6] .
Z drugiej zaś w badaniach, na przykład United Kingdom Prevention Diabetes Study (UKPDS) wykazano, że ścisła kontrola cukrzycy przynosi spadek ryzyka powikłań mikronaczyniowych, zawałów serca o 18%, a liczby zgonów niezależnie od ich przyczyny o 17% [7, 8] . Leczenie cukrzycy typu 2 polega przede wszystkim na zmianie stylu życia, to jest utrzymywaniu odpowiedniej diety, zwiększeniu aktywności fizycznej i redukcji masy ciała. W dalszej kolejności potrzebne bywają leki doustne, a później insulina i inne preparaty podawane parenteralnie. Wiadomo jednak, że mimo stałego postępu w farmakoterapii skuteczność leczenia jest ograniczona, a dodatkowym czynnikiem niesprzyjają-cym uzyskiwaniu dobrych efektów bywa często słaba współpraca ze strony pacjenta. Wykazano, że obecnie jedynie 37% leczonych osiąga cele terapeutyczne zalecane przez towarzystwa diabetologiczne [9] . Dlatego wciąż szuka się skuteczniejszych sposobów leczenia cukrzycy. Należą do nich między innymi przedstawiana 
Modulacja kurczliwości żołądka
System kontroli spożywania posiłków jest jednym z kluczowych elementów układu regulującego homeostazę energetyczną. Mózg uzyskuje w sposób ciągły informacje o aktualnych zasobach energetycznych ustroju, przepływach energii między narządami waż-nymi dla życia, ilości i składzie przyswajanego pokarmu oraz o bieżących potrzebach energetycznych poszczególnych tkanek [10, 11] . Spożyty posiłek aktywuje w ścianie żołądka receptory wrażliwe na rozciągnięcie, co skutkuje powstaniem impulsów elektrycznych z następową zmianą napięcia mięśni gładkich. Te słabe impulsy, pojawiające się głównie w początkowej fazie jedzenia, są odpowiedzialne za kurczliwość żołądka. Jej wzrost, będący następstwem rozciągnięcia tego organu, jest z kolei źródłem impulsów przewodzonych za pośrednictwem włókien aferentnych nerwu błędnego do jądra pasma samotnego (NTS, nucleus tractus solitarii), pola najdalszego (AP, area postrema) i ośrodków regulatorowych w mózgu celem wytworzenia uczucia sytości [12, 13] . Wyniki pierwszych badań prowadzonych na zwierzętach wykazały, że możliwe jest umieszczenie w ścianie żołądka elektrod pozwalających na odbiór sygnałów elektrycznych powstających w trakcie jedzenia, zwłaszcza na początku posiłku, i ich potencjalizacja z następowym zwiększeniem kurczliwości i amplitudy bodźców przesyłanych za pomocą włókien nerwu błędnego do mózgu [14, 15] . Obserwacje te posłużyły do stworzenia systemu DIAMOND™ (dawna nazwa Tantalus) -nowatorskiego sposobu leczenia cukrzycy typu 2 u osób z otyłością. Generowana stymulacja jest -wskutek jej synchronizacji z endogennym rytmem fal wolnych -zgodna z naturalną podstawową aktywnością elektryczną żołądka. Sygnały nie zmieniają częstości naturalnego rytmu żołądka, a jedynie zwiększają odpowiedź na bodźce (ryc. 1). Naturalnie pojawiająca się aktywność elektryczna podlega automatycznej modulacji tylko w czasie spożywania posiłku. Taki algorytm działania zapobiega powstaniu zjawiska tolerancji, którego można by oczekiwać w warunkach ciągłej pracy systemu. Zwiększenie aktywności mechanicznej żołądka już we wczesnej fazie jedzenia szybko powoduje stan odpowiadający sytuacji po zaspokojeniu łaknienia w końcowej fazie spożywania posiłku. W badaniach przedklinicznych prowadzonych na zwierzętach (gryzonie, psy) potwierdzono wzrost impulsacji w aferentnych włóknach nerwu błędnego w odpowiedzi na zwiększenie kurczliwości żołądka 
